CPLX4
gene geneOn this page
Also known as CPX-IV
Summary
CPLX4 (complexin 4, HGNC:24330) is a protein-coding gene on chromosome 18q21.32, encoding Complexin-4 (Q7Z7G2). Complexin that regulates SNARE protein complex-mediated synaptic vesicle fusion.
This gene likely encodes a member of the complexin family. The encoded protein may be involved in synaptic vesicle exocytosis.
Source: NCBI Gene 339302 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 17 total
- GTEx eGene: eQTL in 2 tissues, sQTL in 0 (q < 0.05)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.73 (unconstrained)
- MANE Select transcript:
NM_181654
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:24330 |
| Approved symbol | CPLX4 |
| Name | complexin 4 |
| Location | 18q21.32 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | CPX-IV |
| Ensembl gene | ENSG00000166569 |
| Ensembl biotype | protein_coding |
| OMIM | 609586 |
| Entrez | 339302 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 3 protein_coding
MANE Select: ENST00000299721
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2
ENST00000299721, ENST00000587244, ENST00001131795
RefSeq mRNA: 1 — MANE Select: NM_181654
NM_181654
CCDS: CCDS11973
Canonical transcript exons
ENST00000299721 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001104260 | 59312685 | 59312772 |
| ENSE00001104263 | 59318296 | 59318649 |
| ENSE00001104265 | 59295402 | 59296925 |
Expression profiles
Bgee: expression breadth broad, 18 present calls, max score 81.23.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.2702 / max 2378.9175, expressed in 19 samples.
Highest expression (Bgee): male germ line stem cell (sensu Vertebrata) in testis, cerebellar cortex, cerebellum, cerebellar hemisphere, hemisphere of cerebellum.
Genetic regulation across tissues (GTEx eQTL / sQTL)
CPLX4 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 2 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
2 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Brain Cerebellum | eqtl | 2.9e-02 | +0.32 | 18:60023027:C:T |
| Brain Cerebellar Hemisphere | eqtl | 3.4e-02 | +0.30 | 18:59283565:T:G |
FANTOM5 promoters
3 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 172193 | 1.3741 | 14 |
| 172192 | 0.5667 | 10 |
| 172194 | 0.3294 | 12 |
Top tissues by expression
showing 100 of 114 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 81.23 | gold quality |
| cerebellar cortex | UBERON:0002129 | 58.31 | gold quality |
| cerebellum | UBERON:0002037 | 58.29 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 57.98 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 57.73 | gold quality |
| islet of Langerhans | UBERON:0000006 | 50.24 | gold quality |
| colonic epithelium | UBERON:0000397 | 46.24 | gold quality |
| sural nerve | UBERON:0015488 | 40.96 | gold quality |
| bone marrow cell | CL:0002092 | 40.74 | gold quality |
| ventricular zone | UBERON:0003053 | 40.10 | gold quality |
| pancreas | UBERON:0001264 | 39.29 | gold quality |
| granulocyte | CL:0000094 | 37.20 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 36.37 | gold quality |
| ganglionic eminence | UBERON:0004023 | 35.49 | gold quality |
| apex of heart | UBERON:0002098 | 35.40 | gold quality |
| bone marrow | UBERON:0002371 | 35.23 | gold quality |
| tonsil | UBERON:0002372 | 35.13 | gold quality |
| muscle tissue | UBERON:0002385 | 34.51 | gold quality |
| body of pancreas | UBERON:0001150 | 33.59 | gold quality |
| lymph node | UBERON:0000029 | 32.80 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 32.63 | silver quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| leukocyte | CL:0000738 | 32.08 | gold quality |
| endometrium | UBERON:0001295 | 32.02 | gold quality |
| monocyte | CL:0000576 | 31.89 | gold quality |
| blood | UBERON:0000178 | 30.91 | gold quality |
| brain | UBERON:0000955 | 30.87 | gold quality |
| calcaneal tendon | UBERON:0003701 | 30.86 | gold quality |
| prefrontal cortex | UBERON:0000451 | 30.30 | gold quality |
| stromal cell of endometrium | CL:0002255 | 29.87 | gold quality |
| urinary bladder | UBERON:0001255 | 28.75 | gold quality |
| thoracic aorta | UBERON:0001515 | 28.74 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 28.74 | gold quality |
| ascending aorta | UBERON:0001496 | 28.72 | gold quality |
| cortex of kidney | UBERON:0001225 | 28.49 | gold quality |
| corpus callosum | UBERON:0002336 | 28.49 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 28.39 | silver quality |
| frontal cortex | UBERON:0001870 | 28.36 | gold quality |
| popliteal artery | UBERON:0002250 | 28.32 | gold quality |
| tibial artery | UBERON:0007610 | 28.32 | gold quality |
| metanephros cortex | UBERON:0010533 | 28.19 | gold quality |
| duodenum | UBERON:0002114 | 28.14 | gold quality |
| placenta | UBERON:0001987 | 27.78 | gold quality |
| material anatomical entity | UBERON:0000465 | 27.46 | gold quality |
| multicellular organism | UBERON:0000468 | 27.46 | gold quality |
| primary visual cortex | UBERON:0002436 | 27.43 | gold quality |
| adrenal tissue | UBERON:0018303 | 27.31 | gold quality |
| myometrium | UBERON:0001296 | 27.25 | gold quality |
| right adrenal gland | UBERON:0001233 | 27.13 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 27.01 | gold quality |
| adenohypophysis | UBERON:0002196 | 26.74 | silver quality |
| spleen | UBERON:0002106 | 26.65 | gold quality |
| heart left ventricle | UBERON:0002084 | 26.60 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 26.55 | gold quality |
| cerebral cortex | UBERON:0000956 | 26.48 | gold quality |
| vermiform appendix | UBERON:0001154 | 26.42 | gold quality |
| rectum | UBERON:0001052 | 26.30 | gold quality |
| right frontal lobe | UBERON:0002810 | 26.28 | gold quality |
| right ovary | UBERON:0002118 | 26.26 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 26.03 | gold quality |
| putamen | UBERON:0001874 | 26.00 | gold quality |
| gall bladder | UBERON:0002110 | 25.98 | gold quality |
| heart | UBERON:0000948 | 25.95 | gold quality |
| prostate gland | UBERON:0002367 | 25.79 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 25.75 | gold quality |
| colon | UBERON:0001155 | 25.62 | gold quality |
| skin of abdomen | UBERON:0001416 | 25.61 | gold quality |
| intestine | UBERON:0000160 | 25.59 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 25.47 | silver quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 25.46 | gold quality |
| minor salivary gland | UBERON:0001830 | 25.41 | gold quality |
| small intestine | UBERON:0002108 | 25.28 | gold quality |
| right lung | UBERON:0002167 | 25.09 | gold quality |
| lung | UBERON:0002048 | 24.94 | gold quality |
| body of uterus | UBERON:0009853 | 24.71 | gold quality |
| uterine cervix | UBERON:0000002 | 24.65 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 24.62 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 24.54 | gold quality |
| ectocervix | UBERON:0012249 | 24.50 | gold quality |
| lower esophagus | UBERON:0013473 | 24.46 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 24.45 | gold quality |
| adipose tissue | UBERON:0001013 | 24.41 | gold quality |
| omental fat pad | UBERON:0010414 | 24.40 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 24.35 | gold quality |
| caudate nucleus | UBERON:0001873 | 24.28 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 24.27 | gold quality |
| transverse colon | UBERON:0001157 | 24.18 | gold quality |
| tibial nerve | UBERON:0001323 | 24.08 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 24.08 | gold quality |
| right atrium auricular region | UBERON:0006631 | 24.07 | gold quality |
| esophagus | UBERON:0001043 | 24.02 | gold quality |
| ovary | UBERON:0000992 | 23.98 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 23.79 | gold quality |
| left coronary artery | UBERON:0001626 | 23.76 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 23.46 | gold quality |
| esophagus mucosa | UBERON:0002469 | 23.21 | gold quality |
| thyroid gland | UBERON:0002046 | 23.15 | gold quality |
| left ovary | UBERON:0002119 | 22.58 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 22.52 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7316 | yes | 30.30 |
| E-ANND-3 | yes | 3.26 |
HPA expression
RNA tissue specificity: Tissue enriched
35 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Retina | tissue | 291.7 | high |
| Superior colliculi | tissue | 10.6 | |
| Choroid plexus | tissue | 1.7 | |
| Cerebellum | tissue | 1.6 | low |
| Postcentral gyrus | tissue | 0.9 | |
| Cerebral cortex | tissue | 0.7 | not detected |
| Motor cortex | tissue | 0.7 | |
| Putamen | tissue | 0.7 | |
| Hippocampal formation | tissue | 0.7 | |
| Entorhinal cortex | tissue | 0.7 | |
| Somatosensory cortex | tissue | 0.7 | |
| Retrosplenial cortex | tissue | 0.7 | |
| Amygdala | tissue | 0.6 | |
| Retrosplenial and cingulate cortex | tissue | 0.6 | |
| Septum | tissue | 0.6 | |
| Temporal cortex | tissue | 0.6 | |
| Pons | tissue | 0.5 | |
| Basal ganglia | tissue | 0.5 | not detected |
| Midbrain | tissue | 0.5 | |
| Hypothalamus | tissue | 0.5 | |
| Hippocampus | tissue | 0.5 | not detected |
| Periaqueductal gray | tissue | 0.5 | |
| Occipital cortex | tissue | 0.5 | |
| Insular cortex | tissue | 0.5 | |
| Prefrontal cortex | tissue | 0.4 | |
| Nucleus accumbens | tissue | 0.4 | |
| Locus coeruleus | tissue | 0.4 | |
| Olfactory bulb | tissue | 0.4 | |
| Thalamus | tissue | 0.3 | |
| Substantia nigra | tissue | 0.3 | |
| Ventral forebrain | tissue | 0.3 | |
| Medulla oblongata | tissue | 0.2 | |
| Spinal cord | tissue | 0.2 | |
| Corpus callosum | tissue | 0.2 | |
| Testis | tissue | 0.1 | not detected |
Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — Cerebellar cortex (2.7), Flocculonodular lobe (2.7), Vermis (2.0), Supraoptic nucleus (1.8), Paraventricular nucleus (0.8).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting CPLX4 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 65 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6873-3P | 100.00 | 71.42 | 2626 |
| HSA-MIR-6833-3P | 100.00 | 70.63 | 3197 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-146A-5P | 99.96 | 68.93 | 988 |
| HSA-MIR-146B-5P | 99.96 | 69.13 | 977 |
| HSA-MIR-7153-5P | 99.94 | 68.89 | 1006 |
| HSA-MIR-6780A-5P | 99.88 | 66.69 | 2776 |
| HSA-MIR-579-3P | 99.86 | 71.66 | 3628 |
| HSA-MIR-4503 | 99.85 | 71.45 | 1869 |
| HSA-MIR-664B-3P | 99.84 | 71.65 | 3590 |
| HSA-MIR-6756-5P | 99.82 | 67.97 | 2466 |
| HSA-MIR-6817-3P | 99.79 | 68.35 | 2126 |
| HSA-MIR-6885-3P | 99.75 | 70.36 | 3187 |
| HSA-MIR-4306 | 99.72 | 70.50 | 3630 |
| HSA-MIR-4729 | 99.69 | 72.18 | 4233 |
| HSA-MIR-6766-5P | 99.68 | 67.70 | 2325 |
| HSA-MIR-9851-3P | 99.63 | 69.68 | 1110 |
| HSA-MIR-4516 | 99.61 | 67.78 | 3390 |
| HSA-MIR-6861-3P | 99.60 | 68.46 | 444 |
| HSA-MIR-12123 | 99.52 | 71.79 | 2990 |
| HSA-MIR-155-5P | 99.35 | 70.16 | 1509 |
| HSA-MIR-185-5P | 99.35 | 68.60 | 2497 |
| HSA-MIR-4644 | 99.35 | 69.12 | 2514 |
| HSA-MIR-593-5P | 99.34 | 69.50 | 965 |
| HSA-MIR-7515 | 99.31 | 68.22 | 1795 |
| HSA-MIR-4311 | 99.31 | 70.47 | 3041 |
| HSA-MIR-1264 | 99.25 | 66.81 | 1317 |
Functional genomics
gnomAD constraint: pLI 4.18e-06, LOEUF 1.73, missense Z 0.268 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000299721 — one region, missense o/e 1.00.
Cross-species orthologs
7 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | cplx4b | ENSDARG00000059486 |
| danio_rerio | cplx4a | ENSDARG00000059978 |
| mus_musculus | Cplx4 | ENSMUSG00000024519 |
| rattus_norvegicus | Cplx4 | ENSRNOG00000016928 |
| drosophila_melanogaster | cpx | FBGN0041605 |
| caenorhabditis_elegans | WBGENE00010520 | |
| caenorhabditis_elegans | cpx-1 | WBGENE00022271 |
Paralogs (3): CPLX2 (ENSG00000145920), CPLX1 (ENSG00000168993), CPLX3 (ENSG00000213578)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:2685803) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 5 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| increased circulating alanine transaminase level | 1 |
| abnormal rod electrophysiology | 1 |
| abnormal eye electrophysiology | 1 |
| decreased mean corpuscular hemoglobin | 1 |
| increased circulating total protein level | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Bos taurus | Q0IIE0 | 96.8% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| CCBE1 | protein-coding | 147372 |
| LMAN1 | protein-coding | 3998 |
| GRP | protein-coding | 2922 |
| RAX | protein-coding | 30062 |
| SEC11C | protein-coding | 90701 |
Protein
Protein identifiers
Complexin-4 — Q7Z7G2 (reviewed: Q7Z7G2)
Alternative names: Complexin IV
All UniProt accessions (2): Q7Z7G2, K7EM04
UniProt curated annotations — full annotation on UniProt →
Function. Complexin that regulates SNARE protein complex-mediated synaptic vesicle fusion. Required for the maintenance of synaptic ultrastructure in the adult retina. Positively regulates synaptic transmission through synaptic vesicle availability and exocytosis of neurotransmitters at photoreceptor ribbon synapses in the retina. Suppresses tonic photoreceptor activity and baseline ’noise’ by suppression of Ca(2+) vesicle tonic release and the facilitation of evoked synchronous and asynchronous Ca(2+) vesicle release.
Subunit / interactions. Weakly binds to the SNARE core complex containing SNAP25, VAMP2 and STX1A.
Subcellular location. Synapse. Cell membrane.
Post-translational modifications. Farnesylation mediates presynaptic targeting and is important for function in neurotransmitter release.
Similarity. Belongs to the complexin/synaphin family.
RefSeq proteins (1): NP_857637* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR008849 | Synaphin | Family |
Pfam: PF05835
UniProt features (6 total): chain 1, propeptide 1, region of interest 1, compositionally biased region 1, modified residue 1, lipid moiety-binding region 1
Structure
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q7Z7G2-F1 | 74.26 | 0.19 |
Human Protein Atlas
Protein class: Predicted intracellular proteins
Protein evidence: Evidence at protein level
Antibody reliability (HPA): IH enhanced
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2)
| Type | Positions |
|---|---|
| Cysteine methyl ester | 157 |
| S-farnesyl cysteine | 157 |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
MSigDB gene sets: 72 (showing top):
GOBP_REGULATION_OF_VESICLE_FUSION, GOBP_VESICLE_ORGANIZATION, GOBP_MEMBRANE_FUSION, GOBP_NEUROTRANSMITTER_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_EXOCYTOSIS, GOBP_VESICLE_FUSION_TO_PLASMA_MEMBRANE, GOBP_ORGANELLE_MEMBRANE_FUSION, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, GOBP_REGULATION_OF_NEUROTRANSMITTER_TRANSPORT, GOBP_SECRETION, GOBP_SIGNAL_RELEASE, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION
GO Biological Process (6): visual perception (GO:0007601), synaptic vesicle exocytosis (GO:0016079), regulation of synaptic vesicle fusion to presynaptic active zone membrane (GO:0031630), modulation of chemical synaptic transmission (GO:0050804), neurotransmitter transport (GO:0006836), exocytosis (GO:0006887)
GO Molecular Function (3): SNARE binding (GO:0000149), syntaxin binding (GO:0019905), protein binding (GO:0005515)
GO Cellular Component (4): plasma membrane (GO:0005886), SNARE complex (GO:0031201), terminal bouton (GO:0043195), synapse (GO:0045202)
GO top-level categories
26 GO namespaces:
| Category | Terms |
|---|---|
| presynapse | 2 |
| sensory perception of light stimulus | 1 |
| neurotransmitter secretion | 1 |
| regulated exocytosis | 1 |
| establishment of localization in cell | 1 |
| vesicle-mediated transport in synapse | 1 |
| synaptic vesicle cycle | 1 |
| signal release from synapse | 1 |
| regulation of vesicle fusion | 1 |
| synaptic vesicle fusion to presynaptic active zone membrane | 1 |
| regulation of synaptic vesicle membrane organization | 1 |
| chemical synaptic transmission | 1 |
| regulation of trans-synaptic signaling | 1 |
| transport | 1 |
| vesicle-mediated transport | 1 |
| secretion by cell | 1 |
| vesicle fusion to plasma membrane | 1 |
| protein binding | 1 |
| SNARE binding | 1 |
| binding | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cytoplasm | 1 |
| membrane protein complex | 1 |
| axon terminus | 1 |
| cell junction | 1 |
Protein interactions and networks
STRING
showing 15 of 634 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CPLX4 | VAMP1 | P23763 | 791 |
| CPLX4 | STX1A | Q16623 | 733 |
| CPLX4 | SNAP25 | P13795 | 710 |
| CPLX4 | CPLX1 | O14810 | 645 |
| CPLX4 | P84086 | P84086 | 600 |
| CPLX4 | CABCOCO1 | Q8IVU9 | 504 |
| CPLX4 | STARD6 | P59095 | 488 |
| CPLX4 | CCDC146 | Q8IYE0 | 477 |
| CPLX4 | TERB1 | Q8NA31 | 472 |
| CPLX4 | CRX | O43186 | 467 |
| CPLX4 | LMAN1 | P49257 | 467 |
| CPLX4 | SNPH | O15079 | 467 |
| CPLX4 | CCDC68 | Q9H2F9 | 461 |
| CPLX4 | OTX2 | P32243 | 460 |
| CPLX4 | ABHD14A | Q9BUJ0 | 449 |
IntAct
Human interaction partners of CPLX4 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
showing 30 of 93 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| ADIPOQ | physical association | 0.560 | 3 |
| AGTRAP | physical association | 0.560 | 3 |
| AIG1 | physical association | 0.560 | 3 |
| AOC3 | physical association | 0.560 | 3 |
| APOD | physical association | 0.560 | 3 |
| AQP1 | physical association | 0.560 | 3 |
| AQP9 | physical association | 0.560 | 3 |
| ASGR1 | physical association | 0.560 | 3 |
| ATP6V0C | physical association | 0.560 | 3 |
| BNIP2 | physical association | 0.560 | 3 |
| C5 | physical association | 0.560 | 3 |
| CACNG1 | physical association | 0.560 | 3 |
| CCL4L1 | physical association | 0.560 | 3 |
| CD81 | physical association | 0.560 | 3 |
| CDIPT | physical association | 0.560 | 3 |
| CDS2 | physical association | 0.560 | 3 |
| CLDND2 | physical association | 0.560 | 3 |
| CLEC4G | physical association | 0.560 | 3 |
| CLN6 | physical association | 0.560 | 3 |
| CMTM5 | physical association | 0.560 | 3 |
| CNIH1 | physical association | 0.560 | 3 |
| CTXN3 | physical association | 0.560 | 3 |
| CYB5B | physical association | 0.560 | 3 |
| CYBC1 | physical association | 0.560 | 3 |
| CYP4F2 | physical association | 0.560 | 3 |
| DEFB127 | physical association | 0.560 | 3 |
| EMD | physical association | 0.560 | 3 |
| GAD2 | physical association | 0.560 | 3 |
| GIMAP1 | physical association | 0.560 | 3 |
| GRM2 | physical association | 0.560 | 3 |
BioGRID (117 interactions; top human partners by supporting records): ACTA2 (Affinity Capture-MS; 2 records), CBX5 (Affinity Capture-MS; 2 records), CST1 (Affinity Capture-MS; 2 records), EFHD1 (Affinity Capture-MS; 2 records), IPPK (Affinity Capture-MS; 2 records), MAPK3 (Affinity Capture-MS; 2 records), MICU2 (Affinity Capture-MS; 2 records), SPTB (Affinity Capture-MS; 2 records), ADIPOQ (Two-hybrid), AGTRAP (Two-hybrid), AIG1 (Two-hybrid), AOC3 (Two-hybrid), APOD (Two-hybrid), AQP1 (Two-hybrid), AQP9 (Two-hybrid)
Disease & clinical
Genetic variants
Variant evidence for CPLX4: 17 ClinVar records (0 pathogenic / likely pathogenic); 4 GWAS associations.
ClinVar
17 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 17 |
| Likely benign | 0 |
| Benign | 0 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 29 predictions of 147):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 18:59296928 | acceptor_gain | 1.0000 | |
| 18:59296926–59296927 | acceptor_loss | 0.9900 | 6 |
| 18:59296930 | acceptor_gain | 0.9900 | |
| 18:59312683–59312684 | donor_loss | 0.9800 | 5 |
| 18:59312683 | donor_loss | 0.9700 | |
| 18:59312773–59312774 | acceptor_loss | 0.9600 | 6 |
| 18:59318294–59318295 | donor_loss | 0.9600 | 5 |
| 18:59318291 | donor_loss | 0.9500 | 2 |
| 18:59318294 | donor_loss | 0.9500 | |
| 18:59312780 | acceptor_loss | 0.9400 |
AlphaMissense
332 missense substitutions predicted likely pathogenic (of 1,096 scored), across 105 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D89 | 8 | 0.980 | 0.995 |
| R70 | 7 | 0.959 | 0.996 |
| F63 | 7 | 0.904 | 0.975 |
| M40 | 7 | 0.863 | 0.975 |
| C157 | 7 | 0.839 | 0.962 |
| R74 | 6 | 0.982 | 0.997 |
| R78 | 6 | 0.979 | 0.997 |
| K80 | 6 | 0.977 | 0.989 |
| Y81 | 6 | 0.934 | 0.988 |
| R59 | 6 | 0.919 | 0.990 |
| M109 | 6 | 0.898 | 0.965 |
| K67 | 6 | 0.896 | 0.954 |
| G39 | 6 | 0.875 | 0.959 |
| M160 | 6 | 0.834 | 0.885 |
| P103 | 6 | 0.831 | 0.916 |
| D60 | 6 | 0.830 | 0.933 |
| R82 | 6 | 0.796 | 0.881 |
| E44 | 6 | 0.752 | 0.846 |
| Y48 | 5 | 0.909 | 0.969 |
| A71 | 5 | 0.894 | 0.993 |
HPA cancer prognostics
RNA cancer specificity: Not detected
Disease associations
OMIM: gene MIM:609586 | disease phenotypes:
GWAS associations
4 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST006976_20 | Macular thickness | 7e-24 |
| GCST008309_9 | Cardiac troponin-I levels | 1e-11 |
| GCST003837_7 | Chronotype | 7e-10 |
| GCST003838_15 | Morning vs. evening chronotype | 1e-6 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0010071 | cardiac troponin I measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
9 total (human), top 9 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | increases methylation, affects cotreatment | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression, affects cotreatment | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| bisphenol S | increases methylation | 1 |
| Fulvestrant | affects cotreatment, increases methylation | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Lead | affects expression | 1 |
| Lipopolysaccharides | affects response to substance, increases expression, affects cotreatment | 1 |
| Cadmium Chloride | increases expression | 1 |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.